Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:60080
Name Her2-receptor negative breast cancer
Definition A breast cancer that is characterized by the absence of Her2 receptors.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer Her2-receptor negative breast cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant Capivasertib + Paclitaxel Her2-receptor negative breast cancer no benefit detail...
FGFR1 amp Pazopanib Her2-receptor negative breast cancer predicted - sensitive detail...
RB1 K240Sfs*22 TP53 R248W Fulvestrant + Palbociclib Her2-receptor negative breast cancer predicted - resistant detail...
RB1 I101fs RB1 E268* RB1 V654fs RB1 T738_R775del Fulvestrant + Palbociclib Her2-receptor negative breast cancer predicted - resistant detail...
RB1 H483Y Letrozole + Ribociclib Her2-receptor negative breast cancer predicted - resistant detail...
PIK3CA mutant Alpelisib Her2-receptor negative breast cancer sensitive detail...
PIK3CA wild-type Alpelisib Her2-receptor negative breast cancer no benefit detail...
FBXW7 mutant LY3039478 Her2-receptor negative breast cancer predicted - sensitive detail...
CD274 positive Pembrolizumab Her2-receptor negative breast cancer predicted - sensitive detail...
PIK3CA mutant Everolimus Her2-receptor negative breast cancer no benefit detail...
PIK3CA exon10 Everolimus Her2-receptor negative breast cancer predicted - sensitive detail...
PIK3CA exon21 Everolimus Her2-receptor negative breast cancer no benefit detail...
PIK3CA H1047R Everolimus Her2-receptor negative breast cancer no benefit detail...
PIK3CA E545K Everolimus Her2-receptor negative breast cancer no benefit detail...
PIK3CA E542K Everolimus Her2-receptor negative breast cancer no benefit detail...
FGFR1 amp Lucitanib Her2-receptor negative breast cancer predicted - sensitive detail...
FGFR1 over exp Lucitanib Her2-receptor negative breast cancer predicted - sensitive detail...
PTEN R130* Alpelisib + Letrozole Her2-receptor negative breast cancer predicted - resistant detail...
ATM T2333fs ATM neg BAY1895344 Her2-receptor negative breast cancer predicted - sensitive detail...
PIK3CA act mut Alpelisib + Nab-paclitaxel Her2-receptor negative breast cancer predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib Her2-receptor negative breast cancer predicted - sensitive detail...
PIK3CA H1047R STX-478 Her2-receptor negative breast cancer sensitive detail...
PIK3CA H1047L HS-10352 Her2-receptor negative breast cancer predicted - sensitive detail...
PIK3CA H1047R HS-10352 Her2-receptor negative breast cancer predicted - sensitive detail...
PIK3CA E542K HS-10352 Her2-receptor negative breast cancer predicted - sensitive detail...
PIK3CA E545D HS-10352 Her2-receptor negative breast cancer predicted - sensitive detail...
PIK3CA E545K HS-10352 Her2-receptor negative breast cancer predicted - sensitive detail...
FGFR2 T319I PIK3CA N345K PIK3CA E453K Inavolisib Her2-receptor negative breast cancer predicted - resistant detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00764972 Phase Ib/II Sorafenib + Vinorelbine Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer Unknown status CAN 0
NCT00921115 Phase II Anastrozole Fulvestrant Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. Completed USA 0
NCT00971737 Phase II Trastuzumab Cyclophosphamide Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer Completed USA 0
NCT01036087 Phase II Carboplatin + Nab-paclitaxel + Panitumumab Cyclophosphamide + Epirubicin + Fluorouracil Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer Completed USA 0
NCT01116648 Phase Ib/II Olaparib Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting USA 0
NCT01145430 Phase I Pegylated liposomal doxorubicin + Veliparib Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer Completed USA 0
NCT01262027 Phase II Dovitinib TKI258 for Metastatic Inflammatory Breast Cancer Patients Completed USA 0
NCT01272037 Phase III Anastrozole Letrozole Tamoxifen Exemestane Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Active, not recruiting USA | FRA | ESP | CAN 6
NCT01292655 Phase I BMS-906024 Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors Completed USA | CAN | AUS 0
NCT01351909 Phase I Cyclophosphamide Veliparib Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Active, not recruiting USA 0
NCT01437566 Phase II Apitolisib Fulvestrant Pictilisib Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 14
NCT01441947 Phase II Cabozantinib + Fulvestrant Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer Active, not recruiting USA 0
NCT01467310 Phase I Trametinib Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 Completed USA 0
NCT01479244 Phase III E75 Sargramostim Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Completed USA | GBR | FRA | DEU | CAN 8
NCT01484041 Phase Ib/II Dovitinib Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer Terminated USA 0
NCT01528345 Phase II Dovitinib + Fulvestrant Fulvestrant Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Terminated USA | ITA | FRA | ESP | BEL | AUT 9
NCT01560416 Phase II Fulvestrant Ganetespib Fulvestrant With or Without Ganetespib in HR+ Breast Cancer Active, not recruiting USA 0
NCT01572727 Phase II Buparlisib + Paclitaxel Paclitaxel A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT01610284 Phase III Buparlisib + Fulvestrant Fulvestrant Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)r Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 19
NCT01633060 Phase III Fulvestrant Buparlisib + Fulvestrant A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 13
NCT01670877 Phase II Neratinib Neratinib + Trastuzumab Fulvestrant + Neratinib + Trastuzumab Fulvestrant + Neratinib Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Completed USA | CAN 0
NCT01674140 Phase III Goserelin Anastrozole Letrozole Leuprolide Everolimus Tamoxifen Exemestane S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3) Active, not recruiting USA 1
NCT01698918 Phase II Everolimus + Exemestane Everolimus + Letrozole Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Completed USA | GBR | FRA | ESP 9
NCT01757327 Phase II Sonidegib LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Withdrawn 0
NCT01776008 Phase II Goserelin + MK2206 Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer Terminated USA 0
NCT01779050 Phase II Trastuzumab Docetaxel Cyclophosphamide + Epirubicin Paclitaxel Cyclophosphamide + Epirubicin + Fluorouracil Carboplatin + Docetaxel Cyclophosphamide + Docetaxel Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Terminated USA 0
NCT01791478 Phase I Alpelisib + Letrozole BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer Active, not recruiting USA 0
NCT01792050 Phase II Docetaxel Indoximod Paclitaxel Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Completed USA 1
NCT01797120 Phase II Everolimus + Fulvestrant Fulvestrant Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Completed USA 0
NCT01803282 Phase I Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab Safety and Tolerability Study in Solid Tumors Completed USA 0
NCT01823835 Phase II GDC-0810 A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer Terminated USA | ESP 2
NCT01837602 Phase I cMet CAR RNA T Cells Targeting Breast Cancer Completed USA 0
NCT01894451 Phase I Bevacizumab Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy Completed USA 0
NCT01905592 Phase III Niraparib A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO) Terminated USA | ITA | GBR | FRA | ESP | CAN | BEL 7
NCT01918306 Phase Ib/II Cisplatin Cisplatin + Pictilisib GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer Terminated USA 0
NCT01923168 Phase II Buparlisib + Letrozole Letrozole Alpelisib + Letrozole Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Completed USA | ITA | ESP | DEU | CAN | BEL | AUT | AUS 9
NCT01953588 Phase III Anastrozole Fulvestrant Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Active, not recruiting USA 1
NCT01958021 Phase III Letrozole + Ribociclib Letrozole Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 19
NCT01963481 Phase II Cyclophosphamide Exemestane Exemestane and Cyclophosphamide for Metastatic Breast Cancer Completed USA 0
NCT01964924 Phase II Trametinib + Uprosertib Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Completed USA 0
NCT01969643 Phase I Ladiratuzumab vedotin Ladiratuzumab vedotin + Trastuzumab A Safety Study of SGN-LIV1A in Breast Cancer Patients Completed USA 0
NCT02010021 Phase I Letrozole Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. Completed USA 0
NCT02032277 Phase III Cyclophosphamide + Doxorubicin Veliparib Carboplatin Carboplatin + Paclitaxel A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT02032823 Phase III Olaparib Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 14
NCT02038699 Phase Ib/II ONC201 A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer Withdrawn USA 0
NCT02040857 Phase II Exemestane Palbociclib Tamoxifen Letrozole Anastrozole A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer Completed USA 0
NCT02049957 Phase Ib/II Fulvestrant + Sapanisertib Exemestane + Sapanisertib Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer Completed USA | FRA | BEL 0
NCT02057133 Phase I Abemaciclib + Loperamide + Pertuzumab + Trastuzumab Abemaciclib + Fulvestrant + LY3023414 Abemaciclib + Letrozole Abemaciclib + Exemestane Abemaciclib Abemaciclib + Everolimus + Exemestane Abemaciclib + Anastrozole Abemaciclib + Tamoxifen Abemaciclib + Trastuzumab A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread Active, not recruiting USA 0
NCT02074878 Phase I Crizotinib + Sunitinib CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer Terminated USA 0
NCT02088684 Phase Ib/II Buparlisib + Fulvestrant + Ribociclib Fulvestrant + Ribociclib Alpelisib + Fulvestrant + Ribociclib Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer Completed USA | ITA | GBR | FRA | ESP 3
NCT02095184 Phase 0 Anastrozole Letrozole GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients Recruiting USA 0
NCT02107703 Phase III Abemaciclib + Fulvestrant Fulvestrant A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (MONARCH 2) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 12
NCT02115048 Phase II Afatinib Letrozole Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone Terminated USA | ESP 2
NCT02120417 Phase II Capecitabine + Ruxolitinib Capecitabine A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer Terminated USA | ITA | GBR | FRA | ESP 1
NCT02137837 Phase III Everolimus + Fulvestrant Anastrozole + Everolimus + Fulvestrant Fulvestrant S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Terminated USA 0
NCT02142868 Phase III Letrozole + Palbociclib Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate No longer available USA | CAN 0
NCT02154776 Phase I Buparlisib + Letrozole + Ribociclib Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet) Completed USA | ESP 0
NCT02157051 Phase I Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer Active, not recruiting USA 0
NCT02163694 Phase III Carboplatin + Paclitaxel + Veliparib Carboplatin + Paclitaxel A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 27
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed USA 0
NCT02187991 Phase II Paclitaxel Alisertib + Paclitaxel Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Active, not recruiting USA 0
NCT02188745 Phase II Exemestane Estradiol Anastrozole Letrozole ER Reactivation Therapy for Breast Cancer (POLLY) Active, not recruiting USA 0
NCT02204098 Phase I Mammaglobin-A Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Active, not recruiting USA 0
NCT02236572 Phase II Everolimus Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score Terminated USA 0
NCT02246621 Phase III Abemaciclib + Anastrozole + Letrozole Anastrozole + Letrozole A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT02248090 Phase I AZD9496 AZD9496 First Time in Patients Ascending Dose Study Completed USA | GBR 1
NCT02258451 Phase II Everolimus + Exemestane Radium Ra 223 dichloride Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT 9
NCT02258464 Phase II Radium Ra 223 dichloride Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer Terminated USA | GBR | FRA | ESP | DEU | CAN | AUT 13
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed 0
NCT02260661 Phase I Fulvestrant AZD8835 Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours Completed USA | GBR 0
NCT02264678 Phase Ib/II Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting USA | GBR | FRA | ESP | CAN | BEL | AUS 2
NCT02269670 Phase II Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole Phase II Study of Everolimus Beyond Progression Terminated USA 0
NCT02273752 Phase II Everolimus Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated USA 0
NCT02273973 Phase II Taselisib Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) Completed USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 13
NCT02278120 Phase III Goserelin + Ribociclib + Tamoxifen Goserelin + Tamoxifen Anastrozole + Goserelin Goserelin + Letrozole Goserelin + Letrozole + Ribociclib Anastrozole + Goserelin + Ribociclib Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL | AUS 22
NCT02282345 Phase II Talazoparib Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer Completed USA 0
NCT02286843 Phase I Trastuzumab Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy? Completed USA 0
NCT02291913 Phase II Everolimus + Tamoxifen Anastrozole + Everolimus Everolimus + Fulvestrant Everolimus + Letrozole Everolimus + Toremifene Everolimus + Exemestane Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer Completed USA 0
NCT02296801 Phase II Palbociclib Letrozole A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer Completed USA | GBR | CAN 0
NCT02301988 Phase II Paclitaxel Ipatasertib A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer Completed USA | ESP 1
NCT02308020 Phase II Abemaciclib A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain Completed USA | ITA | FRA | ESP | CAN | BEL | AUT | AUS 1
NCT02309177 Phase I Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer Completed USA 0
NCT02311933 Phase II Z-endoxifen HCl Tamoxifen Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer Active, not recruiting USA 0
NCT02323191 Phase I Atezolizumab + Emactuzumab A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | ESP | BEL 0
NCT02352025 Phase I S-equol S-equol in Women With Triple Negative Breast Cancer Completed USA 0
NCT02374099 Phase II Azacitidine Fulvestrant Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant Terminated USA | ITA | FRA | ESP | DEU | BEL 0
NCT02379247 Phase Ib/II Alpelisib + Nab-paclitaxel BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer Completed USA 0
NCT02384239 Phase II Fulvestrant + Palbociclib Palbociclib + Tamoxifen A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer Completed USA 0
NCT02384746 Phase I Fulvestrant + Ixazomib Phase I Study of the Combination of MLN9708 and Fulvestrant Terminated USA 0
NCT02387099 Phase II Everolimus Dose EScalation Induction of EvERolimus (Desiree) Completed DEU 0
NCT02389764 Phase II Nintedanib Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC) Terminated USA 0
NCT02401347 Phase II Talazoparib Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors Completed USA 0
NCT02402764 Phase II Selinexor Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC Completed USA 0
NCT02403271 Phase Ib/II Durvalumab + Ibrutinib A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors Completed USA 0
NCT02422615 Phase III Fulvestrant Fulvestrant + Ribociclib Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT02437318 Phase III Alpelisib Fulvestrant Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 21
NCT02441946 Phase II Abemaciclib Loperamide Anastrozole A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Completed USA | ITA | ESP | DEU | CAN | BEL | AUT 3
NCT02448771 Phase Ib/II Bazedoxifene + Palbociclib A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer Completed USA 0
NCT02453620 Phase I Entinostat + Ipilimumab + Nivolumab Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer Active, not recruiting USA 0
NCT02457910 Phase Ib/II Enzalutamide Enzalutamide + Taselisib Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Terminated USA 0
NCT02463032 Phase II Enobosarm Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer Completed USA 0
NCT02476786 Phase II Anastrozole Fulvestrant Goserelin Tamoxifen Exemestane Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Recruiting USA 0
NCT02481050 Phase II Eribulin Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer Completed USA 0
NCT02513394 Phase III Palbociclib PALbociclib CoLlaborative Adjuvant Study (PALLAS) Active, not recruiting USA | ITA | GBR | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT02520063 Phase Ib/II Carotuximab + Everolimus + Letrozole Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer Completed USA 0
NCT02536794 Phase II Durvalumab + Tremelimumab MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer Completed USA 0
NCT02561832 Phase I Cyclophosphamide Olaparib Carboplatin A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer Terminated USA | ESP 0
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed FRA | ESP 1
NCT02586675 Phase I Goserelin Ribociclib + Tamoxifen TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer Completed USA 0
NCT02619669 Phase I Sapanisertib Letrozole Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer Withdrawn USA 0
NCT02626507 Phase I Palbociclib Gedatolisib Goserelin Fulvestrant Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer Unknown status USA 0
NCT02630368 Phase Ib/II Avelumab + Cyclophosphamide + JX-594 Cyclophosphamide + JX-594 Cyclophosphamide A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) Recruiting FRA 0
NCT02630693 Phase II Palbociclib Fulvestrant Tamoxifen Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer Completed CAN 0
NCT02632045 Phase II Fulvestrant + Ribociclib Fulvestrant Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer (MAINTAIN) Active, not recruiting USA 0
NCT02648477 Phase II Letrozole + Pembrolizumab Exemestane + Pembrolizumab Anastrozole + Pembrolizumab Doxorubicin + Pembrolizumab Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer Active, not recruiting USA 0
NCT02651610 Phase II Bavituximab Paclitaxel Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer Withdrawn USA 0
NCT02668666 Phase II Palbociclib + Tamoxifen Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Active, not recruiting USA 0
NCT02684032 Phase I Letrozole Fulvestrant Gedatolisib + Palbociclib A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer Completed USA 0
NCT02692755 Phase II Fulvestrant + Palbociclib Letrozole + Palbociclib Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer (PALINA) Completed USA 0
NCT02712723 Phase II Letrozole + Ribociclib Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer (FELINE) Active, not recruiting USA 0
NCT02732119 Phase Ib/II Everolimus + Exemestane + Ribociclib Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1) Completed USA 0
NCT02738866 Phase II Fulvestrant + Palbociclib Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor Active, not recruiting USA 0
NCT02747004 Phase II Abemaciclib + Loperamide Abemaciclib Abemaciclib + Tamoxifen A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1) Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT 7
NCT02752685 Phase II Nab-paclitaxel + Pembrolizumab Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer Active, not recruiting USA 0
NCT02753686 Phase I Tamoxifen Exemestane Fulvestrant Letrozole Anastrozole Everolimus + Exemestane Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight) Completed CAN 0
NCT02756364 Phase II Fulvestrant + Sapanisertib Fulvestrant MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy Completed USA | ESP 0
NCT02760030 Phase II Fulvestrant + Palbociclib Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery Recruiting USA 0
NCT02761694 Phase I ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations Terminated USA 0
NCT02764541 Phase II Palbociclib Palbociclib + Tamoxifen Letrozole Tamoxifen Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) Active, not recruiting USA 0
NCT02776917 Phase I Cirmtuzumab + Paclitaxel Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer Active, not recruiting USA 0
NCT02778685 Phase II Fulvestrant + Palbociclib + Pembrolizumab Letrozole + Palbociclib + Pembrolizumab Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer Active, not recruiting USA 0
NCT02779751 Phase II Abemaciclib + Pembrolizumab A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Active, not recruiting USA | ITA | FRA | ESP | BEL 2
NCT02792114 Phase I Rimiducid Mesothelin CAR-T cells Cyclophosphamide T-Cell Therapy for Advanced Breast Cancer Active, not recruiting USA 0
NCT02792725 Expanded access Abemaciclib Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer Approved for marketing USA 0
NCT02811497 Phase II Azacitidine + Durvalumab Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) Completed CAN 0
NCT02824575 Phase I Paclitaxel + Rebastinib Eribulin + Rebastinib Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer Terminated USA 0
NCT02849496 Phase II Olaparib Atezolizumab + Olaparib Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer Active, not recruiting USA 0
NCT02860000 Phase II Alisertib + Fulvestrant Alisertib Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer Active, not recruiting USA 0
NCT02871791 Phase Ib/II Everolimus + Exemestane + Palbociclib Palbociclib With Everolimus + Exemestane In BC Completed USA 0
NCT02892734 Phase II Ipilimumab + Nivolumab Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer Terminated USA 0
NCT02936206 Phase I Tamoxifen Fulvestrant Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. Terminated USA 0
NCT02941926 Phase III Letrozole + Ribociclib Leuprolide Goserelin Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC Completed USA | ITA | GBR | FRA | ESP | CAN | BEL | AUT 30
NCT02942355 Phase II Anastrozole + Palbociclib Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer Active, not recruiting USA 0
NCT02953860 Phase II Enzalutamide + Fulvestrant Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer Completed USA 0
NCT02955394 Phase II Fulvestrant Enzalutamide + Fulvestrant Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer Active, not recruiting USA 0
NCT02957968 Phase II Decitabine + Pembrolizumab Cyclophosphamide + Doxorubicin Carboplatin + Paclitaxel Paclitaxel Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Active, not recruiting USA 0
NCT02983604 Phase Ib/II Exemestane Fulvestrant + GS-5829 Exemestane + GS-5829 Fulvestrant GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer Terminated USA 0
NCT03007979 Phase II Goserelin Fulvestrant + Palbociclib Letrozole + Palbociclib Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer Completed USA 0
NCT03018080 Phase II Paclitaxel + Pembrolizumab Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy) Completed USA 0
NCT03044730 Phase II Capecitabine + Pembrolizumab Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Unknown status USA 0
NCT03050398 Phase III Letrozole + Ribociclib A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib Terminated USA 0
NCT03051659 Phase II Eribulin Eribulin + Pembrolizumab A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer Completed USA 0
NCT03051672 Phase II Pembrolizumab Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC Terminated USA 0
NCT03056755 Phase II Alpelisib + Fulvestrant Alpelisib + Letrozole Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 11
NCT03070002 Phase II Denosumab Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells Terminated USA 0
NCT03078751 Phase II Ribociclib Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1) Completed USA 0
NCT03088527 Phase I RAD140 Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer Completed USA 0
NCT03092934 Phase Ib/II LY3295668 A Study of AK-01 (LY3295668) in Solid Tumors Completed CAN 0
NCT03128619 Phase Ib/II Copanlisib + Letrozole + Palbociclib Copanlisib + Letrozole Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer Terminated USA 0
NCT03132467 Phase I Durvalumab + Tremelimumab Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer Active, not recruiting USA 0
NCT03134638 Phase I Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 A Study of SY-1365 in Adult Patients With Advanced Solid Tumors Terminated USA | FRA | CAN 0
NCT03147287 Phase II Palbociclib Fulvestrant + Palbociclib Avelumab + Fulvestrant + Palbociclib Fulvestrant Palbociclib After CDK and Endocrine Therapy (PACE) Active, not recruiting USA 0
NCT03150576 Phase II Carboplatin + Paclitaxel Carboplatin + Olaparib + Paclitaxel Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer (PARTNER) Recruiting GBR 0
NCT03155997 Phase III Abemaciclib Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 28
NCT03166085 Phase I Nab-paclitaxel + PU-H71 PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer Completed USA 0
NCT03219476 Phase II Anastrozole Letrozole Tamoxifen Exemestane Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer Active, not recruiting USA 0
NCT03225547 Phase II Mifepristone + Pembrolizumab Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer Active, not recruiting USA 0
NCT03241810 Phase II Fulvestrant Fulvestrant + Seribantumab Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC) Terminated USA | ESP | DEU | CAN | BEL | AUT 0
NCT03250676 Phase Ib/II H3B-6545 Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer Completed USA | GBR | FRA 0
NCT03280563 Phase Ib/II Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab + Exemestane Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab + Fulvestrant Atezolizumab + Bevacizumab + Tamoxifen Atezolizumab + Fulvestrant + Ipatasertib Fulvestrant Atezolizumab + Fulvestrant A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS HR+BC) Active, not recruiting USA 2
NCT03284723 Phase I Letrozole + Palbociclib + PF-06804103 PF-06804103 PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors Completed USA | ITA | ESP | AUS 2
NCT03285607 Phase I Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer Withdrawn 0
NCT03286842 Phase III Olaparib To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. Completed USA | ITA | GBR | FRA | ESP | DEU | CAN 8
NCT03294694 Phase I Fulvestrant + Ribociclib + Spartalizumab Ribociclib + Spartalizumab Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer Terminated USA 0
NCT03306472 Phase II Letrozole + Megestrol acetate Letrozole A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer (PIONEER) Completed GBR 0
NCT03322215 Phase II Capecitabine Fulvestrant + Palbociclib HR+/HER2- Advanced Breast Cancer and Endocrine Resistance (PASIPHAE) Terminated GBR 1
NCT03326674 Phase III Capecitabine Capecitabine + Tesetaxel Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 9
NCT03329937 Phase I Niraparib Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment Completed USA 0
NCT03332797 Phase I Giredestrant + Palbociclib Giredestrant A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer Active, not recruiting USA | GBR | ESP | AUS 1
NCT03337724 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 21
NCT03344536 Phase Ib/II Debio 1347 + Fulvestrant A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer Completed USA 0
NCT03355157 FDA approved Exemestane + Palbociclib Tamoxifen Paclitaxel Exemestane Capecitabine Palbociclib + Tamoxifen Epirubicin Vinorelbine Fulvestrant + Palbociclib Fulvestrant Letrozole Letrozole + Palbociclib A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA) Unknown status DEU 0
NCT03356860 Phase Ib/II Cyclophosphamide + Durvalumab + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE) Completed BEL 0
NCT03363893 Phase Ib/II Samuraciclib Fulvestrant + Samuraciclib Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Completed USA | GBR 0
NCT03366844 Phase Ib/II Pembrolizumab Breast Cancer Study of Preoperative Pembrolizumab + Radiation Active, not recruiting USA 0
NCT03393845 Phase II Fulvestrant + Pembrolizumab Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients Active, not recruiting USA 0
NCT03412643 Phase II Cyclophosphamide + Doxorubicin Paclitaxel + Pertuzumab + Trastuzumab Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12) Recruiting USA 0
NCT03430518 Phase I Durvalumab + Eribulin Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer Completed USA 0
NCT03439735 Phase II Palbociclib Fulvestrant + Palbociclib Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC Recruiting USA 0
NCT03455270 Phase I G1T48 G1T48 + Palbociclib G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer Completed USA | BEL 5
NCT03471663 Phase I D-0502 + Palbociclib D-0502 A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer Completed USA 1
NCT03473639 Phase I Capecitabine + Entinostat A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy (Breast49) Completed USA 0
NCT03477396 Phase II Ribociclib Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer Completed USA 0
NCT03499353 Phase II Talazoparib Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer Terminated USA 0
NCT03515798 Phase II Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer (PELICAN) Recruiting FRA | BEL 0
NCT03519178 Phase II PF-06873600 A Study of PF-06873600 in People With Cancer Active, not recruiting USA | CAN 4
NCT03524170 Phase I Bintrafusp alfa + Radiotherapy Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Completed USA 0
NCT03554044 Phase I Letrozole + Talimogene laherparepvec Talimogene laherparepvec + Tamoxifen Exemestane + Talimogene laherparepvec Fulvestrant + Talimogene laherparepvec Anastrozole + Talimogene laherparepvec Nab-paclitaxel + Talimogene laherparepvec Carboplatin + Gemcitabine + Talimogene laherparepvec Paclitaxel + Talimogene laherparepvec Talimogene Laherparepvec With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer Active, not recruiting USA 0
NCT03555877 Phase II Anastrozole Fulvestrant Fulvestrant + Ribociclib Letrozole Exemestane + Ribociclib Letrozole + Ribociclib Anastrozole + Ribociclib Exemestane Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (AMICA) Completed DEU 0
NCT03560531 Phase I Palbociclib + ZN-c5 ZN-c5 A Study of ZN-c5 in Subjects With Breast Cancer Completed USA 8
NCT03566485 Phase Ib/II Atezolizumab + Idasanutlin Atezolizumab + Cobimetinib Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer Terminated USA 0
NCT03568422 Phase Ib/II CFI-402257 + Paclitaxel CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer Active, not recruiting CAN 0
NCT03595059 Phase I Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors Active, not recruiting USA | ESP | CAN | AUS 6
NCT03609047 Phase II Palbociclib Cyclophosphamide + Epirubicin Paclitaxel Cyclophosphamide + Docetaxel Cyclophosphamide + Doxorubicin Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches) Active, not recruiting ITA | GBR | FRA | ESP | DEU | BEL 3
NCT03616587 Phase I Camizestrant Camizestrant + Palbociclib Camizestrant + Everolimus Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1) Active, not recruiting USA | GBR | ESP 0
NCT03620643 Phase II Crizotinib Crizotinib + Fulvestrant Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo) Active, not recruiting GBR 0
NCT03624543 Phase II CFI-400945 CFI-400945 in Patients With Advanced/Metastatic Breast Cancer Active, not recruiting CAN 0
NCT03628066 Phase II Goserelin + Letrozole + Palbociclib Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer Completed USA | CAN 0
NCT03633331 Phase II Fulvestrant + Letrozole + Palbociclib Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer Active, not recruiting USA 0
NCT03650894 Phase II Bicalutamide + Ipilimumab + Nivolumab Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Active, not recruiting USA 0
NCT03659136 Phase II Everolimus + Exemestane + Xentuzumab Everolimus + Exemestane The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 2
NCT03685331 Phase I Fulvestrant + Olaparib + Palbociclib HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer Active, not recruiting USA 0
NCT03685591 Phase I PF-06952229 Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229 PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Terminated USA 0
NCT03691493 Phase II Letrozole + Palbociclib Palbociclib + Tamoxifen Fulvestrant + Palbociclib Anastrozole + Palbociclib Exemestane + Palbociclib Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE) Completed USA 0
NCT03701334 Phase III Ribociclib A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 10
NCT03725436 Phase I ALRN-6924 + Paclitaxel ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors Active, not recruiting USA 0
NCT03774472 Phase Ib/II Hydroxychloroquine + Letrozole + Palbociclib Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer Active, not recruiting USA 0
NCT03781063 Phase II Lasofoxifene Fulvestrant Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Active, not recruiting USA | CAN 1
NCT03789110 Phase II Ipilimumab + Nivolumab NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer Active, not recruiting USA 0
NCT03803761 Phase Ib/II Copanlisib + Fulvestrant A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer Withdrawn USA 0
NCT03804944 Phase II CDX-301 CDX-301 + Pembrolizumab Pembrolizumab Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV) Recruiting USA 0
NCT03809988 Phase II Fulvestrant Fulvestrant + Palbociclib Letrozole Letrozole + Palbociclib PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) Completed ITA | GBR | FRA | ESP | DEU 1
NCT03820830 Phase III Anastrozole Exemestane Anastrozole + Palbociclib Letrozole Letrozole + Palbociclib Exemestane + Palbociclib Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR) Recruiting ITA | FRA | ESP | AUT 2
NCT03822468 Phase II Goserelin + Letrozole + Ribociclib Anastrozole + Ribociclib Anastrozole + Goserelin + Ribociclib Letrozole + Ribociclib Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE) Active, not recruiting USA | FRA | DEU | CAN | BEL | AUT 17
NCT03840200 Phase Ib/II Ipatasertib + Rucaparib A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Completed USA | ITA | ESP | AUS 1
NCT03854903 Phase I Bosutinib + Palbociclib Bosutinib + Fulvestrant + Palbociclib WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor Active, not recruiting USA 0
NCT03858972 Phase II Capecitabine + Tesetaxel Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC (CONTESSA 2) Terminated USA | ESP | CAN | AUS 2
NCT03870919 FDA approved Palbociclib Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients (PALATINE) Active, not recruiting FRA 0
NCT03875573 Phase II Durvalumab Durvalumab + Oleclumab Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay) Active, not recruiting FRA | BEL 0
NCT03901339 Phase III Eribulin Gemcitabine Vinorelbine Capecitabine Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (TROPiCS-02) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 1
NCT03906669 Phase II Letrozole Tamoxifen A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. (WinPro) Recruiting AUS 0
NCT03911973 Phase Ib/II Gedatolisib + Talazoparib Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Active, not recruiting USA 0
NCT03917082 Phase II Tamoxifen Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (LALEAST) Active, not recruiting CAN 0
NCT03939897 Phase Ib/II Abemaciclib + Fulvestrant Abemaciclib + Copanlisib + Fulvestrant Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer Active, not recruiting USA 0
NCT03944434 Phase II Anastrozole + Ribociclib Letrozole + Ribociclib Leuprolide Goserelin Triptorelin FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (FACILE) Active, not recruiting ITA 0
NCT03950570 Phase I ORIN1001 + Paclitaxel ORIN1001 ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer Active, not recruiting USA 0
NCT03952325 Phase II Pembrolizumab + Tesetaxel Nivolumab + Tesetaxel Tesetaxel Atezolizumab + Tesetaxel Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO) Terminated USA 2
NCT03955939 Phase I LY3295668 + Midazolam LY3295668 A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body Completed USA | BEL 0
NCT03956654 FDA approved Letrozole + Ribociclib A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer (RibOB) Active, not recruiting BEL 0
NCT03959891 Phase I Fulvestrant + Ipatasertib + Palbociclib Ipatasertib Fulvestrant + Ipatasertib AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) Active, not recruiting USA 0
NCT03988114 FDA approved Abemaciclib + Anastrozole Abemaciclib + Letrozole A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer (proMONARCH) Withdrawn USA | ITA | DEU | BEL | AUT 4
NCT03990896 Phase II Talazoparib Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial Recruiting USA 0
NCT04024436 Phase II Fulvestrant + Futibatinib Futibatinib A Study of TAS-120 in Patients With Metastatic Breast Cancer Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN 1
NCT04031885 FDA approved Abemaciclib + Fulvestrant A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer Terminated USA 1
NCT04038489 Phase II Aspirin + Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer (Breast 51) Withdrawn USA 0
NCT04042480 Phase I SGN-CD228A A Study of SGN-CD228A in Advanced Solid Tumors Terminated USA | ITA | GBR | FRA | ESP 0
NCT04052555 Phase I Berzosertib Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer Active, not recruiting USA 0
NCT04053322 Phase II Durvalumab + Fulvestrant + Olaparib Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF) Active, not recruiting FRA 0
NCT04055493 Phase III Ribociclib Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle) Recruiting DEU 0
NCT04059484 Phase II Amcenestrant Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3) Active, not recruiting USA | ITA | FRA | ESP | CAN | BEL | AUS 16
NCT04060862 Phase III Fulvestrant + Ipatasertib + Palbociclib Fulvestrant + Palbociclib A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150) Completed USA | GBR | ESP | CAN | AUS 3
NCT04072952 Phase Ib/II Palbociclib + Vepdegestrant Vepdegestrant A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC) Recruiting USA 0
NCT04075604 Phase II Anastrozole + Palbociclib Anastrozole + Nivolumab + Palbociclib A Study of Neoadjuvant Nivolumab + Abemaciclib or Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer (CheckMate 7A8) Completed USA | FRA | ESP | DEU | CAN | BEL | AUS 1
NCT04088032 Phase I Abemaciclib + Durvalumab + Exemestane Abemaciclib + Anastrozole + Durvalumab Abemaciclib + Durvalumab + Letrozole Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer Withdrawn USA 0
NCT04090567 Phase II Cediranib + Olaparib Ceralasertib + Olaparib Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Recruiting USA 0
NCT04092673 Phase Ib/II Fulvestrant + Zotatifin Zotatifin Sotorasib + Zotatifin Abemaciclib + Fulvestrant + Zotatifin Trastuzumab + Zotatifin Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin) Recruiting USA 0
NCT04095273 Phase I BAY1895344 + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Completed USA | GBR | ESP | DEU 1
NCT04102618 Phase I Atezolizumab + Pelareorep Atezolizumab + Pelareorep + Trastuzumab Letrozole + Pelareorep Atezolizumab + Letrozole + Pelareorep A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1) Terminated ESP 0
NCT04113863 Phase II Anastrozole Anastrozole + Tretinoin Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (ATRA) Recruiting ITA 0
NCT04130152 Phase I Letrozole + Palbociclib Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy Completed ESP 0
NCT04132817 Phase I Nab-paclitaxel + Nivolumab Ipilimumab + Nab-paclitaxel + Nivolumab A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread Completed USA 0
NCT04134598 Phase III Tamoxifen Letrozole Anastrozole Exemestane ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged >=70 Years Early Stage Breast Cancer (EUROPA) Recruiting ITA 0
NCT04142060 Phase II Enzalutamide Targeting PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer (ARIANNA) Terminated ESP 0
NCT04142892 Phase I Onapristone Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer (ONAWA) Completed ESP 0
NCT04158362 Phase III Capecitabine Abemaciclib + Fulvestrant Abemaciclib + Letrozole Paclitaxel Abemaciclib + Anastrozole Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (AMBRE) Recruiting FRA 0
NCT04174352 Phase I Tamoxifen FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer Recruiting USA 0
NCT04176848 Phase II CFI-400945 + Durvalumab CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer Unknown status CAN 0
NCT04182516 Phase I NMS-03305293 Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Unknown status USA | ITA 1
NCT04185311 Phase I Ipilimumab + Nivolumab + Talimogene laherparepvec Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Terminated USA 0
NCT04188548 Phase I Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356 A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) Active, not recruiting USA | FRA | ESP | BEL | AUS 3
NCT04191382 Phase II Letrozole Amcenestrant Phase 2 Window Study of SAR439859 Versus Letrozole in ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4) Terminated USA | ITA | FRA | ESP | BEL 4
NCT04191499 Phase II Fulvestrant + Palbociclib Fulvestrant + Inavolisib + Palbociclib A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 19
NCT04214288 Phase II Camizestrant Fulvestrant A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 8
NCT04215146 Phase II Paclitaxel Avelumab + Paclitaxel + Pelareorep Paclitaxel + Pelareorep A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Active, not recruiting USA 0
NCT04220476 Phase II Letrozole + Palbociclib CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (CIMER) Withdrawn 0
NCT04225117 Phase II Enfortumab vedotin-ejfv A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Recruiting USA | CAN 1
NCT04227327 Phase II Abemaciclib + Letrozole Abemaciclib + Anastrozole Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (HERMIONE-7) Active, not recruiting ITA 0
NCT04240106 Phase II Niraparib Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) Completed ESP 0
NCT04243616 Phase II Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer Recruiting USA 0
NCT04251169 Phase II Paclitaxel + Pembrolizumab Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression (TATEN) Active, not recruiting ESP 0
NCT04274933 Phase I Capecitabine + Venetoclax A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy Terminated USA | DEU 2
NCT04288089 Phase I H3B-6545 + Palbociclib A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer Active, not recruiting USA | GBR 0
NCT04293393 Phase II Cyclophosphamide + Docetaxel + Doxorubicin Abemaciclib + Letrozole Abemaciclib + Goserelin + Letrozole Abemaciclib + Letrozole + Leuprolide Cyclophosphamide + Doxorubicin + Paclitaxel Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (CARABELA) Active, not recruiting ESP 0
NCT04300790 Phase II Alpelisib + Fulvestrant + Metformin Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (METALLICA) Recruiting ESP 0
NCT04305236 Phase II Abemaciclib + Fulvestrant Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer Terminated USA 0
NCT04305496 Phase III Capivasertib + Fulvestrant Fulvestrant Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 10
NCT04305834 Phase II Abemaciclib Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer Recruiting USA 0
NCT04316169 Phase I Abemaciclib + Anastrozole + Hydroxychloroquine Abemaciclib + Fulvestrant + Hydroxychloroquine Abemaciclib + Hydroxychloroquine Abemaciclib + Hydroxychloroquine + Letrozole Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer Withdrawn USA 0
NCT04318223 Phase II Palbociclib Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy Unknown status ITA 0
NCT04333706 Phase Ib/II Capecitabine Capecitabine + Sarilumab A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER) Recruiting USA 0
NCT04352777 Phase II Abemaciclib + Letrozole Abemaciclib + Anastrozole Abemaciclib + Fulvestrant Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer Active, not recruiting USA 0
NCT04432454 Phase II Abemaciclib + Lasofoxifene Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII) Active, not recruiting USA 0
NCT04436744 Phase II Giredestrant + Palbociclib Anastrozole + Palbociclib A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer Completed USA | ESP | DEU | AUS 7
NCT04443348 Phase II Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) Recruiting USA 0
NCT04448886 Phase II Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Active, not recruiting USA 0
NCT04460430 Phase II Fulvestrant + Neratinib Neratinib + Tamoxifen Exemestane + Neratinib Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer (NEREA) Terminated ESP 1
NCT04478266 Phase III Letrozole + Palbociclib Amcenestrant + Goserelin + Palbociclib Goserelin + Letrozole + Palbociclib Amcenestrant + Palbociclib SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer (AMEERA-5) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT04481113 Phase I Abemaciclib + Niraparib Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer Active, not recruiting USA 0
NCT04483505 Phase I Fulvestrant + Palbociclib + Rogaratinib Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (ROGABREAST) Completed ESP 0
NCT04489173 Phase II Trifluridine-tipiracil hydrochloride TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer (TIBET) Recruiting 1
NCT04494425 Phase III Capecitabine Nab-paclitaxel Trastuzumab deruxtecan Paclitaxel Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 18
NCT04498520 Phase I Abexinostat + Fulvestrant + Palbociclib Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Withdrawn 0
NCT04504331 Phase I Fulvestrant + Infigratinib + Palbociclib Infigratinib + Tamoxifen Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer Terminated USA 0
NCT04505826 Phase Ib/II Palazestrant A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer Active, not recruiting USA | AUS 0
NCT04514159 Phase I Abemaciclib + ZN-c5 A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer Completed USA 1
NCT04546009 Phase III Letrozole + Palbociclib Giredestrant + Palbociclib A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT04553133 Phase II PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 PF-07104091 as a Single Agent and in Combination Therapy Recruiting USA 3
NCT04556773 Phase I Fulvestrant + Trastuzumab deruxtecan Durvalumab + Paclitaxel + Trastuzumab deruxtecan Capivasertib + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Anastrozole + Trastuzumab deruxtecan A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08) Active, not recruiting USA | FRA | CAN | BEL | AUS 5
NCT04563507 Phase II Letrozole + Palbociclib Combined Immunotherapies in Metastatic ER+ Breast Cancer Recruiting USA 0
NCT04565054 Phase III Abemaciclib Tamoxifen Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC (ADAPTlate) Recruiting DEU 0
NCT04567420 Phase II Fulvestrant + Palbociclib DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer (DARE) Recruiting USA 0
NCT04568616 Phase II Letrozole Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) (NAOMI) Recruiting USA 0
NCT04576455 Phase II Fulvestrant Giredestrant A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) Active, not recruiting USA | GBR | DEU | AUS 13
NCT04579380 Phase II Trastuzumab + Tucatinib Fulvestrant + Trastuzumab + Tucatinib Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations Active, not recruiting USA | ITA | GBR | ESP | DEU | BEL 4
NCT04584255 Phase II Dostarlimab-gxly + Niraparib Niraparib Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Recruiting USA 0
NCT04584853 Phase III Abemaciclib PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (POETIC-A) Recruiting GBR 0
NCT04585724 Phase I Abemaciclib Palbociclib Ribociclib Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases Withdrawn 0
NCT04586270 Phase I TAS0612 A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer Recruiting USA | FRA 0
NCT04588298 Phase II Camizestrant A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3) Completed GBR 2
NCT04595565 Phase III Sacituzumab govitecan-hziy Cisplatin Carboplatin Capecitabine Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA) Recruiting ITA | FRA | ESP | DEU | BEL | AUT 2
NCT04596150 Phase II CX-2009 CX-072 + CX-2009 Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer Completed USA | ESP 1
NCT04603183 Phase II Abemaciclib + Fulvestrant + Letrozole Paclitaxel ABemaciclib, ET +/- paclItaxel in aGgressive HR+/HER2- MBC trIaL (ABIGAIL) Active, not recruiting ITA | ESP 1
NCT04606446 Phase I PF-07248144 Fulvestrant + Palbociclib + PF-07248144 Fulvestrant + PF-07248144 Letrozole + Palbociclib + PF-07248144 Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) Recruiting USA | AUS 3
NCT04610528 Phase I Patritumab deruxtecan A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3) Active, not recruiting ESP 0
NCT04614194 Phase II Letrozole Abemaciclib + Letrozole Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib Recruiting USA 0
NCT04616248 Phase I CDX-1140 + CDX-301 + Poly ICLC In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Recruiting USA 0
NCT04647487 Phase I LY3484356 A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2) Completed USA | GBR | FRA | ESP | DEU | BEL 0
NCT04647916 Phase II Sacituzumab govitecan-hziy Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases Recruiting USA 0
NCT04650581 Phase III Fulvestrant Fulvestrant + Ipatasertib Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER) Recruiting CAN | AUS 1
NCT04655183 Phase Ib/II Niraparib + VX-803 Niraparib Study of M4344 in Combination With Niraparib Withdrawn 0
NCT04657679 Phase 0 Fulvestrant + Ribociclib Letrozole + Ribociclib Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (LEANORA) Terminated USA 0
NCT04665921 Phase I SGN-STNV A Study of SGN-STNV in Advanced Solid Tumors Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN 0
NCT04682431 Phase I Pembrolizumab + PY159 PY159 A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04691375 Phase I Pembrolizumab + PY314 PY314 A Study of PY314 in Subjects With Advanced Solid Tumors Active, not recruiting USA 0
NCT04703920 Phase I Belinostat + Talazoparib Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer Recruiting USA 0
NCT04711252 Phase III Anastrozole + Palbociclib Camizestrant + Palbociclib A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 18
NCT04711824 Phase Ib/II Nab-paclitaxel Carboplatin + Gemcitabine Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA) Recruiting USA 0
NCT04714619 Phase II Anastrozole + CB-103 CB-103 + Letrozole CB-103 Plus NSAI In Luminal Advanced Breast Cancer (CAILA) Terminated ESP 0
NCT04720664 Phase II Methoxsalen + Phenytoin + Sirolimus + SM88 Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer (OASIS) Terminated USA 0
NCT04726332 Phase I Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) Active, not recruiting USA 0
NCT04738292 Phase II Fulvestrant + Onapristone Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) Terminated USA 0
NCT04756505 Phase I Bintrafusp alfa + NHS-IL12 Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial Withdrawn 0
NCT04756765 Phase II Talazoparib Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer Recruiting USA 0
NCT04762979 Phase II Alpelisib + Fulvestrant Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer Recruiting USA 0
NCT04791384 Phase Ib/II Abemaciclib + Elacestrant Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer Recruiting USA 0
NCT04797728 Phase I Elacestrant Elacestrant in Preoperative Setting, a Window of Opportunity Study (ELIPSE) Completed ESP 0
NCT04841148 Phase II Hydroxychloroquine Avelumab + Palbociclib Hydroxychloroquine + Palbociclib Avelumab Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY) Recruiting USA 0
NCT04851613 Phase I Afuresertib + Fulvestrant Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer Active, not recruiting USA 1
NCT04862663 Phase III Capivasertib + Fulvestrant + Ribociclib Abemaciclib + Capivasertib + Fulvestrant Capivasertib + Fulvestrant + Palbociclib Fulvestrant + Palbociclib Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 13
NCT04869943 Phase III Exemestane Enobosarm Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer (ARTEST) Terminated USA | ESP 2
NCT04872608 Phase I Letrozole + Onapristone + Palbociclib A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Withdrawn USA 0
NCT04895358 Phase III Nab-paclitaxel Nab-paclitaxel + Pembrolizumab Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Capecitabine Pegylated liposomal doxorubicin Paclitaxel Pegylated liposomal doxorubicin + Pembrolizumab Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS 22
NCT04895761 Phase I Letrozole + Maveropepimut-S Cyclophosphamide + Letrozole + Maveropepimut-S Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer Active, not recruiting USA 0
NCT04901299 Phase II Fulvestrant + Neratinib Fulvestrant + Neratinib In Breast Cancer (HER2-Signal) Withdrawn USA 0
NCT04906395 Phase III Anastrozole + Leuprolide + Tamoxifen Exemestane + Leuprolide + Tamoxifen Letrozole + Leuprolide + Tamoxifen Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA) Recruiting USA | CAN 4
NCT04915755 Phase III Niraparib Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 18
NCT04920708 Phase II Fulvestrant + Ribociclib Fulvestrant + Ipatasertib + Palbociclib Fulvestrant + Palbociclib Abemaciclib + Fulvestrant Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM) Recruiting GBR 0
NCT04923542 Phase Ib/II Abemaciclib Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases Recruiting USA 0
NCT04925284 Phase I XB002 Nivolumab + XB002 Study of XB002 in Subjects With Solid Tumors (JEWEL-101) Recruiting USA | ITA | GBR | FRA | ESP | BEL | AUS 1
NCT04946864 Phase Ib/II APG-2575 + Palbociclib APG-2575 A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer Recruiting USA 0
NCT04961996 Phase III Exemestane Giredestrant Letrozole Anastrozole A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 44
NCT04964934 Phase III Abemaciclib + Camizestrant Letrozole + Palbociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Abemaciclib + Anastrozole Camizestrant + Palbociclib Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT04965766 Phase II Patritumab deruxtecan Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST) Recruiting FRA 0
NCT04975308 Phase III Exemestane Abemaciclib + LY3484356 LY3484356 Fulvestrant A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3) Recruiting USA | ITA | FRA | ESP | DEU | BEL | AUT | AUS 14
NCT04985266 Phase II Exemestane + Tamoxifen Fulvestrant + Palbociclib Anastrozole + Tamoxifen Letrozole + Tamoxifen A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER) Recruiting GBR | FRA 0
NCT04991480 Phase Ib/II ART4215 + Talazoparib ART4215 A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors Active, not recruiting USA | GBR 0
NCT05033756 Phase II Olaparib + Pembrolizumab Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (COMPRENDO) Recruiting DEU 0
NCT05038735 Phase III Alpelisib + Fulvestrant Fulvestrant Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5) Recruiting ITA | FRA | ESP | DEU | CAN | BEL 11
NCT05064085 Phase I Capecitabine + Cemiplimab Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer Active, not recruiting USA 0
NCT05065411 Phase III Fulvestrant Exemestane Abemaciclib + Enobosarm Everolimus + Exemestane Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (VERU-024) Terminated USA 0
NCT05067972 Phase I PF-07260437 A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) Terminated USA 1
NCT05069038 Phase II Palbociclib Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy Recruiting USA 0
NCT05079360 Phase II Everolimus + Exemestane Exemestane VERU-111 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer Withdrawn USA 0
NCT05080842 Phase I AC682 A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer Active, not recruiting USA 0
NCT05085002 Phase II G1T38 + Letrozole Fulvestrant + G1T38 A Study of Lerociclib in Participants With Advanced Breast Cancer Terminated USA | ITA | BEL 3
NCT05090358 Phase II Alpelisib + Fulvestrant Alpelisib + Canagliflozin + Fulvestrant Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer Active, not recruiting USA 0
NCT05095207 Phase Ib/II Abemaciclib + Bicalutamide Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer Recruiting USA 0
NCT05098210 Phase I NeoVax + Nivolumab + Poly ICLC Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer Recruiting USA 0
NCT05101564 Phase II Amcenestrant Alpelisib Infigratinib Tamoxifen Letrozole Amcenestrant + Letrozole Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer Recruiting USA 0
NCT05104866 Phase III Gemcitabine Capecitabine Datopotamab deruxtecan Vinorelbine Eribulin A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 12
NCT05134922 Expanded access Gedatolisib Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009 Available USA 0
NCT05143229 Phase I Alpelisib + Sacituzumab govitecan-hziy Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer (ASSET) Recruiting USA 0
NCT05159518 Phase I PRT2527 A Study of PRT2527 in Participants With Advanced Solid Tumors Completed USA 0
NCT05159778 Phase II Pembrolizumab + PGG beta-glucan Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) Completed USA 0
NCT05169567 Phase III Fulvestrant Abemaciclib + Fulvestrant Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH) Active, not recruiting USA | ITA | FRA | ESP | BEL 11
NCT05183828 FDA approved Letrozole Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer Suspended USA 0
NCT05187832 Phase I AND019 A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer Recruiting USA 0
NCT05191004 Phase Ib/II NUV-422 Fulvestrant + NUV-422 Fulvestrant Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Withdrawn USA 0
NCT05194072 Phase I SGN-B7H4V A Study of SGN-B7H4V in Advanced Solid Tumors Recruiting USA | ITA | GBR | ESP | DEU | CAN 0
NCT05203445 Phase II Olaparib + Pembrolizumab A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer Recruiting USA 0
NCT05207709 Phase III Letrozole + Ribociclib Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Paclitaxel Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (HARMONIA) Recruiting USA | ESP 1
NCT05216432 Phase I RLY-2608 Fulvestrant + RLY-2608 First-in-Human Study of Mutant-selective PI3Kalpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer Recruiting USA | ITA | FRA | ESP 0
NCT05243641 Phase Ib/II Capmatinib + Neratinib Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test Recruiting USA 0
NCT05251714 Phase Ib/II CFI-402257 CFI-402257 + Fulvestrant CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer Recruiting USA 0
NCT05252416 Phase Ib/II BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant (VELA) Study of BLU-222 in Advanced Solid Tumors Recruiting USA | ITA | GBR 0
NCT05261269 Phase I DAN-222 DAN-222 + Niraparib A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer Completed USA 0
NCT05262400 Phase II Letrozole + PF-07104091 + PF-07220060 Fulvestrant + PF-07104091 + PF-07220060 PF-07104091 + PF-07220060 A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors Recruiting USA | ESP 7
NCT05296746 Phase II Ribociclib Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS) Recruiting FRA | ESP 1
NCT05304962 Phase I RGT-419B First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Recruiting USA 0
NCT05305924 Phase II Fulvestrant Abemaciclib + Fulvestrant Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer Recruiting USA 0
NCT05306340 Phase III Everolimus + Fulvestrant Everolimus + Tamoxifen Everolimus + Exemestane Everolimus + Giredestrant A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) Recruiting USA | ITA | GBR | ESP | DEU 8
NCT05307705 Phase I Abemaciclib + Anastrozole + LOXO-783 Abemaciclib + Exemestane + LOXO-783 Abemaciclib + Letrozole + LOXO-783 LOXO-783 + Paclitaxel Fulvestrant + LOXO-783 LOXO-783 + LY3484356 Abemaciclib + Fulvestrant + LOXO-783 Abemaciclib + LOXO-783 + LY3484356 Letrozole + LOXO-783 LOXO-783 Anastrozole + LOXO-783 Exemestane + LOXO-783 A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01) Recruiting USA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 4
NCT05340413 Phase II Olaparib Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA) Recruiting ESP 0
NCT05362760 FDA approved Abemaciclib + Exemestane Abemaciclib + Fulvestrant Abemaciclib + Letrozole Abemaciclib + Anastrozole Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA) Recruiting DEU 0
NCT05384119 Phase Ib/II C188-9 + Palbociclib C188-9 + Fulvestrant C188-9 + Ribociclib Fulvestrant Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer Active, not recruiting USA 0
NCT05386108 Phase Ib/II Abemaciclib + Elacestrant Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer (ELECTRA) Recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL 2
NCT05392608 Phase II Alpelisib + Fulvestrant SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) (SEQUEL-Breast) Recruiting 1
NCT05394103 Phase Ib/II Q901 Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors Recruiting USA 1
NCT05417594 Phase Ib/II AZD9574 AZD9574 + Temozolomide Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) Recruiting USA | GBR | ESP | DEU | AUS 2
NCT05438329 Phase Ib/II DB-1305 First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors Recruiting USA 2
NCT05447910 Phase II Letrozole Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer Recruiting USA 0
NCT05452213 FDA approved Ribociclib Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC) Recruiting DEU 0
NCT05455619 Phase Ib/II Alpelisib + Fulvestrant + SDX-7320 Evexomostat Plus Alpelisib and Fulvestrant in Women With the PIK3CA Mutation With HR+/Her2- Breast Cancer (Amelia-1) Recruiting USA 0
NCT05464810 Phase I Letrozole + Simvastatin Letrozole Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer Recruiting USA 0
NCT05467891 Phase II Fulvestrant + Ribociclib Anastrozole + Ribociclib Letrozole + Ribociclib Exemestane + Ribociclib Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR) Recruiting USA 0
NCT05472792 Phase II Toremifene Exemestane Tamoxifen Letrozole Anastrozole Fulvestrant Comparison of Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) (CAMERAN) Recruiting USA 0
NCT05498155 Phase II Olaparib Durvalumab + Olaparib Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (OlympiaN) Recruiting USA | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 1
NCT05501704 Phase II Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Anastrozole + Degarelix Anastrozole + Degarelix Anastrozole ETHAN - ET for Male BC Recruiting USA 0
NCT05501769 Phase I Everolimus + Vepdegestrant ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (TACTIVE-E) Active, not recruiting USA | ESP 0
NCT05501886 Phase III Alpelisib + Fulvestrant Fulvestrant + Gedatolisib + Palbociclib Fulvestrant + Gedatolisib Fulvestrant Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT05504707 Phase I HER2-pulsed DC1 vaccine HER3-primed DC1 vaccine DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER) Recruiting USA 0
NCT05508906 Phase I Alpelisib + Palazestrant Palazestrant + Ribociclib Phase 1b Combo w/ Ribociclib and Alpelisib Recruiting USA | AUS 0
NCT05512364 Phase III Letrozole Anastrozole Exemestane Elacestrant Tamoxifen Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA) Recruiting ITA | FRA | DEU | BEL 1
NCT05514054 Phase III Letrozole Anastrozole Exemestane Tamoxifen LY3484356 A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 22
NCT05524584 Phase II Abemaciclib + Anastrozole + Fulvestrant Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer Recruiting USA 0
NCT05548127 Phase Ib/II Abemaciclib + Vepdegestrant TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) Recruiting USA | ESP | CAN 0
NCT05549505 Phase II Anastrozole Vepdegestrant A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery Active, not recruiting USA | ESP | DEU 1
NCT05554354 Phase II Binimetinib + Fulvestrant Fulvestrant Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial Recruiting USA 1
NCT05563220 Phase Ib/II Alpelisib + Elacestrant Elacestrant + Ribociclib Elacestrant + Everolimus Elacestrant + Palbociclib Abemaciclib + Elacestrant Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE) Recruiting USA 0
NCT05564377 Phase II Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Recruiting USA 1
NCT05569811 Phase II Letrozole + Patritumab deruxtecan Patritumab deruxtecan NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE) Active, not recruiting ESP 0
NCT05573126 Phase Ib/II RAD140 Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer Recruiting USA | GBR 0
NCT05573555 Phase II Ribociclib + Vepdegestrant TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) Recruiting USA | ITA | ESP | CAN 0
NCT05579366 Phase Ib/II PRO1184 PRO1184 for Advanced Solid Tumors (PRO1184-001) Recruiting USA 1
NCT05596409 Phase II Elacestrant ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study (ELCIN) Recruiting USA 1
NCT05607004 Phase II Goserelin + Z-endoxifen HCl Z-endoxifen HCl Exemestane + Goserelin (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE) Recruiting USA 0
NCT05608252 Phase Ib/II Abemaciclib + Fulvestrant + RO5126766 VS-6766+Abema+Fulv in Met HR+/HER- BC Recruiting USA 0
NCT05618613 Phase Ib/II Elacestrant + Onapristone Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer (ELONA) Active, not recruiting USA 0
NCT05620914 Phase I Patritumab deruxtecan A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) Not yet recruiting USA 0
NCT05622058 Phase I ALRN-6924 + Cyclophosphamide + Docetaxel + Doxorubicin A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer Terminated USA 3
NCT05625087 Phase II Fulvestrant + Ribociclib Alpelisib + Fulvestrant Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib (SAFIR 03) Recruiting FRA 0
NCT05633979 Phase I DS-3201b DS-3201b + Trastuzumab deruxtecan Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer Recruiting USA 0
NCT05646862 Phase III Alpelisib + Fulvestrant Fulvestrant + Inavolisib A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121) Recruiting USA | GBR | ESP | CAN | BEL | AUS 8
NCT05653752 Phase I YL202 A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer Recruiting USA 1
NCT05654532 Phase I AC699 Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer Recruiting USA 0
NCT05654623 Phase III Fulvestrant Vepdegestrant A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 21
NCT05655598 Phase I Palbociclib + Pimitespib TAS-116 Plus Palbociclib in Breast and Rb-null Cancer Recruiting USA 0
NCT05659563 Phase II Tamoxifen Giredestrant Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67>=10% (EMPRESS) Recruiting FRA | ESP 0
NCT05660083 Phase II Alpelisib + L-NMMA + Nab-paclitaxel Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) Recruiting USA 0
NCT05664893 Phase Ib/II Ribociclib Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS) (CALHYS) Recruiting FRA 0
NCT05675579 Phase II Pembrolizumab + Sacituzumab govitecan-hziy A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) Recruiting USA 0
NCT05683418 Phase I TOS-358 A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors Recruiting USA 0
NCT05720117 Phase I PYX-201 Study of PYX-201 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05735080 Phase Ib/II INX-315 Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) Recruiting USA | AUS 0
NCT05747794 Phase II Paclitaxel Eftilagimod alpha + Paclitaxel Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy (AIPAC-003) Recruiting USA | ESP | BEL 0
NCT05759949 Phase I Fulvestrant + RLY-5836 RLY-5836 Fulvestrant + Palbociclib + RLY-5836 Abemaciclib + Fulvestrant + RLY-5836 Fulvestrant + Ribociclib + RLY-5836 First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors Active, not recruiting USA 0
NCT05768139 Phase Ib/II Fulvestrant + STX-478 STX-478 First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05774951 Phase III Tamoxifen Exemestane Anastrozole Letrozole Camizestrant A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 29
NCT05791474 Phase Ib/II Capecitabine + Denosumab ATI-2231 + Capecitabine ATI-2231 Bisphosphonate + Capecitabine ATI-2231 With in Advanced Solid Tumor Malignancies Followed by ATI-2231 in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer Withdrawn 0
NCT05826964 Phase II Everolimus + Fulvestrant Exemestane + Ribociclib Everolimus + Tamoxifen Fulvestrant + Ribociclib Everolimus + Exemestane Abemaciclib + Letrozole Anastrozole + Palbociclib Abemaciclib + Anastrozole Alpelisib + Letrozole Abemaciclib + Exemestane Fulvestrant + Palbociclib Alpelisib + Fulvestrant Letrozole + Palbociclib Exemestane + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Fulvestrant Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer Recruiting USA 0
NCT05827081 Phase III Exemestane + Leuprolide + Ribociclib Letrozole + Leuprolide + Ribociclib Goserelin + Letrozole + Ribociclib Anastrozole + Ribociclib Anastrozole + Goserelin + Ribociclib Exemestane + Goserelin + Ribociclib Exemestane + Ribociclib Anastrozole + Leuprolide + Ribociclib Letrozole + Ribociclib Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (Adjuvant WIDER) Recruiting AUS 0
NCT05837455 Phase II Anastrozole NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer Not yet recruiting USA 0
NCT05840211 Phase III Paclitaxel Capecitabine Nab-paclitaxel Sacituzumab govitecan-hziy Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT05867251 Phase Ib/II ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin ARTS-021 Study of ARTS-021 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05870579 Phase I 177Lu-NeoB + Fulvestrant + Ribociclib Goserelin [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2-, GRPR+ Breast Cancer Recruiting FRA | ESP 1
NCT05896566 Phase II Anastrozole + Triptorelin Giredestrant + Triptorelin Giredestrant A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (PREcoopERA) Recruiting ITA | FRA | ESP | DEU 4
NCT05898399 Phase Ib/II Olaparib ART6043 Talazoparib ART6043 + Olaparib ART6043 + Talazoparib Study of ART6043 in Advanced/Metastatic Solid Tumors Patients Recruiting USA 0
NCT05909397 Phase III Letrozole + Palbociclib Palbociclib + Vepdegestrant A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3) Recruiting USA | ITA | ESP | AUS 6
NCT05919108 Phase II Neratinib Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers Not yet recruiting USA 0
NCT05932667 Phase II Fulvestrant + Milademetan Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer (DEMETER) Terminated FRA 0
NCT05952557 Phase III Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Exemestane Abemaciclib + Camizestrant Abemaciclib + Letrozole Abemaciclib + Anastrozole Exemestane Anastrozole Letrozole An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 33
NCT05963984 Phase II Fulvestrant + Samuraciclib Fulvestrant A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC) Recruiting USA | ESP 1
NCT05963997 Phase Ib/II Elacestrant + Samuraciclib A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (SUMIT-ELA) Recruiting USA | GBR | FRA | ESP 0
NCT05967884 Phase II Cemiplimab Cemiplimab + Dupilumab PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer Not yet recruiting CAN 0
NCT05969041 Phase I MT-302 Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) Recruiting AUS 0
NCT05985655 Phase Ib/II GTAEXS617 Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) Recruiting GBR | BEL 0
NCT05986071 Phase Ib/II Fulvestrant + M1774 I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX) Not yet recruiting FRA 0
NCT05996107 Phase I Ribociclib Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer Recruiting USA 0
NCT06001762 Phase II Tamoxifen Exemestane Abemaciclib Anastrozole Letrozole TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer Recruiting USA 0
NCT06014658 Phase I MBRC-101 Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors Recruiting USA 0
NCT06016738 Phase III Fulvestrant Letrozole Anastrozole Palazestrant Exemestane OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01) Recruiting USA | AUS 4
NCT06026657 Phase Ib/II Gemcitabine + TGF-beta-imprinted NK cells Gemcitabine + Naxitamab + TGF-beta-imprinted NK cells Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFbeta-i Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer Recruiting USA 0
NCT06058377 Phase III Cyclophosphamide + Doxorubicin + Durvalumab + Paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer Recruiting USA 0
NCT06062498 Phase II Abemaciclib + Elacestrant Elacestrant Elacestrant + Palbociclib Elacestrant + Ribociclib Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Not yet recruiting USA 0
NCT06065748 Phase III Fulvestrant + Palbociclib Abemaciclib + Fulvestrant Giredestrant + Ribociclib Giredestrant + Palbociclib Abemaciclib + Giredestrant Fulvestrant + Ribociclib A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) Recruiting USA | ESP | CAN | BEL | AUS 10
NCT06066424 Phase I Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) Recruiting USA 0
NCT06084481 Phase I ABBV-400 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 Recruiting USA 2
NCT06099769 Phase II Capecitabine Paclitaxel Enzalutamide Enzalutamide + Mifepristone Eribulin Carboplatin A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer Recruiting USA 0
NCT06105632 Phase III Fulvestrant Everolimus + Exemestane Fulvestrant + PF-07220060 A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment Recruiting USA | CAN | AUS 5
NCT06110793 Phase Ib/II Fulvestrant + Lenvatinib + Pembrolizumab A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer Recruiting USA 0
NCT06112379 Phase III Carboplatin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Capecitabine Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Pembrolizumab Cyclophosphamide + Epirubicin + Pembrolizumab Datopotamab deruxtecan + Durvalumab Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 16
NCT06120283 Phase I BGB-43395 BGB-43395 + Letrozole BGB-43395 + Fulvestrant BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors Recruiting USA | AUS 0
NCT06125522 Phase II Samuraciclib + Vepdegestrant TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) Recruiting USA 1
NCT06167317 Phase I GS-0201 + Sacituzumab govitecan-hziy GS-0201 Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors Recruiting USA 0
NCT06169371 FDA approved Abemaciclib Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) (BRE-09) Recruiting USA 0
NCT06176261 Phase II Datopotamab deruxtecan DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs Recruiting USA 0
NCT06179303 Phase II Tamoxifen Exemestane Abemaciclib Fulvestrant Letrozole Anastrozole Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer Not yet recruiting USA 0
NCT06188520 Phase Ib/II AZD8421 + Camizestrant + Palbociclib AZD8421 + Camizestrant + Ribociclib Abemaciclib + AZD8421 + Camizestrant AZD8421 A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1) Recruiting USA | GBR | AUS 1
NCT06193525 Phase II Talazoparib FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (FUTURE) Recruiting 1
NCT06201234 Phase II Niraparib Elacestrant + Niraparib Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT) Not yet recruiting DEU 0
NCT06206837 Phase I PF-07220060 + Vepdegestrant A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. Recruiting USA 2
NCT06214793 Phase II Taletrectinib Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) Not yet recruiting USA 0
NCT06236269 Phase II Sacituzumab govitecan-hziy HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2) Not yet recruiting ESP 0
NCT06259929 Phase II Abemaciclib + Giredestrant NEOadjuvant Abemaciclib and GIredestrant triaL in Patients With ER-positive, HER2-negative Early Breast Cancer (Neo-AGILE) Not yet recruiting ITA 0
NCT06264921 Phase I NKT3447 A Phase 1 Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors Not yet recruiting USA 0